Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Lark

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 5, 2001
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primateG B Stroup, M W Lark, D F Veber, et al.
Bone|September 12, 2006
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeysS Kumar, L Dare, J A Vasko-Moser, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Journal of Medicinal Chemistry|April 20, 2001
Azepanone-based inhibitors of human and rat cathepsin KR W Marquis, Y Ru, S M LoCastro, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 5, 2001
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primateG B Stroup, M W Lark, D F Veber, et al.
Bone|September 12, 2006
A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeysS Kumar, L Dare, J A Vasko-Moser, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2001
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized ratM W Lark, G B Stroup, R A Dodds, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Journal of Medicinal Chemistry|April 20, 2001
Azepanone-based inhibitors of human and rat cathepsin KR W Marquis, Y Ru, S M LoCastro, et al.
Pageof 8